NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 349)
Posted On: 11/16/2022 3:38:49 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical efficacy readout will be available by second quarter 2Q 2023. Dr. Ujendra Kumar from the University of British Columbia (“UBC”) received grant funding from the Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance to conduct the research, with InMed named as the industry partner. The collaboration project is entitled “Pharmacological characterization of phytocannabinoids and the endocannabinoid system.” “We are pleased that our efforts have led to the identification of two cannabinoid analog candidates to advance to in vivo studies,” said InMed Pharmaceuticals Senior Vice President of Preclinical Research & Development Eric Hsu, PhD, in the press release. “Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant. Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases. This program, in conjunction with the work we are doing within glaucoma, increases our focus on, and expands our pipeline within, the neuroprotection space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical efficacy readout will be available by second quarter 2Q 2023. Dr. Ujendra Kumar from the University of British Columbia (“UBC”) received grant funding from the Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance to conduct the research, with InMed named as the industry partner. The collaboration project is entitled “Pharmacological characterization of phytocannabinoids and the endocannabinoid system.” “We are pleased that our efforts have led to the identification of two cannabinoid analog candidates to advance to in vivo studies,” said InMed Pharmaceuticals Senior Vice President of Preclinical Research & Development Eric Hsu, PhD, in the press release. “Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant. Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases. This program, in conjunction with the work we are doing within glaucoma, increases our focus on, and expands our pipeline within, the neuroprotection space.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼